» Articles » PMID: 19952276

Increased Bone Volume and Correction of HYP Mouse Hypophosphatemia in the Klotho/HYP Mouse

Overview
Journal Endocrinology
Specialty Endocrinology
Date 2009 Dec 3
PMID 19952276
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Inactivating mutations of PHEX cause X-linked hypophosphatemia and result in increased circulating fibroblast growth factor 23 (FGF23). FGF23 action is dependent upon Klotho, which converts FGF receptor 1 into an FGF23-specific receptor. Disruption of Klotho results in a complex bone phenotype and hyperphosphatemia, the converse phenotype of X-linked hypophosphatemia. We examined effects of disrupting both Klotho and PHEX by creating a double-knockout (Klotho/HYP) mouse. The combined disruption corrected the hypophosphatemia in HYP mice, indicating that Klotho is epistatic to PHEX. FGF23 levels remained elevated in all groups except wild-type, indicating that Klotho is necessary for FGF23-dependent phosphaturic activity. 1,25-Dihydroxyvitamin D levels, reduced in HYP mice, were comparably elevated in Klotho and Klotho/HYP mice, demonstrating that Klotho is necessary for FGF23's effect on vitamin D metabolism. Serum PTH levels were reduced in both Klotho and Klotho/HYP mice. Moreover, the Klotho null phenotype persisted in Klotho/HYP, maintaining the runty phenotype and decreased life span of Klotho null mice. Notably, microcomputed tomography analysis demonstrated greater trabecular bone volume fraction in Klotho/HYP mice than that in all other groups (Klotho/HYP, 56.2 +/- 6.3%; Klotho, 32.5 +/- 10.3%; HYP, 8.6 +/- 7.7%; and wild type, 21.4 +/- 3.4%; P < 0.004). Histomorphometric analysis confirmed the markedly increased trabecular bone density in Klotho/HYP mice and the well-established increase in osteoid volume in HYP mice. These observations suggest that with addition of Klotho loss of function, the overabundant osteoid typically produced in HYP mice (but fails to mineralize) is produced and mineralized in the double knockout, resulting in markedly enhanced trabecular bone density.

Citing Articles

Impaired Growth Plate Maturation in XLH Is due to Both Excess FGF23 and Decreased 1,25-Dihydroxyvitamin D Signaling.

Yadav P, Kobelski M, Martins J, Tao T, Liu E, Demay M Endocrinology. 2023; 165(1).

PMID: 38066669 PMC: 10732678. DOI: 10.1210/endocr/bqad186.


Biomechanical Impact of Phosphate Wasting on Articular Cartilage Using the Murine Hyp Model of X-linked hypophosphatemia.

Macica C, Tommasini S JBMR Plus. 2023; 7(10):e10796.

PMID: 37808393 PMC: 10556269. DOI: 10.1002/jbm4.10796.


Cellular and Molecular Alterations Underlying Abnormal Bone Growth in X-Linked Hypophosphatemia.

Fuente R, Garcia-Bengoa M, Fernandez-Iglesias A, Gil-Pena H, Santos F, Lopez J Int J Mol Sci. 2022; 23(2).

PMID: 35055123 PMC: 8778463. DOI: 10.3390/ijms23020934.


Conductive Hearing Loss in the Hyp Mouse Model of X-Linked Hypophosphatemia Is Accompanied by Hypomineralization of the Auditory Ossicles.

Delsmann M, Seist R, Sturznickel J, Schmidt F, Mansour A, Kobelski M J Bone Miner Res. 2021; 36(12):2317-2328.

PMID: 34523743 PMC: 8688200. DOI: 10.1002/jbmr.4443.


Novel anatomic adaptation of cortical bone to meet increased mineral demands of reproduction.

Macica C, King H, Wang M, McEachon C, Skinner C, Tommasini S Bone. 2016; 85:59-69.

PMID: 26825813 PMC: 7429445. DOI: 10.1016/j.bone.2015.12.056.


References
1.
Perwad F, Zhang M, Tenenhouse H, Portale A . Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol. 2007; 293(5):F1577-83. DOI: 10.1152/ajprenal.00463.2006. View

2.
Benet-Pages A, Lorenz-Depiereux B, Zischka H, White K, Econs M, Strom T . FGF23 is processed by proprotein convertases but not by PHEX. Bone. 2004; 35(2):455-62. DOI: 10.1016/j.bone.2004.04.002. View

3.
Tenenhouse H, Martel J, Gauthier C, Segawa H, Miyamoto K . Differential effects of Npt2a gene ablation and X-linked Hyp mutation on renal expression of Npt2c. Am J Physiol Renal Physiol. 2003; 285(6):F1271-8. DOI: 10.1152/ajprenal.00252.2003. View

4.
Fukumoto S, Yamashita T . FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23. Bone. 2007; 40(5):1190-5. DOI: 10.1016/j.bone.2006.12.062. View

5.
Eicher E, SOUTHARD J, Scriver C, Glorieux F . Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci U S A. 1976; 73(12):4667-71. PMC: 431589. DOI: 10.1073/pnas.73.12.4667. View